ozuriftamab vedotin + cetuximab

**Ozuriftamab vedotin + cetuximab** is an investigational combination therapy consisting of two agents: ozuriftamab vedotin, a conditionally active antibody-drug conjugate (ADC) targeting the receptor tyrosine kinase-like orphan receptor ROR2, and cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody. Ozuriftamab vedotin employs a unique mechanism where its targeting antibody (CAB technology) is active primarily in the acidic tumor microenvironment, limiting off-tumor effects, and is conjugated to a cytotoxic payload. Cetuximab is a well-established EGFR inhibitor used in various carcinomas. The combination is under clinical investigation primarily for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), with the approach hypothesized to provide complementary, non-overlapping mechanisms targeting distinct drivers in tumor biology[1][5][8].